U.S., Aug. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07135102) titled 'A Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of [225Ac]Ac-PSMA-XT Injection in Patients With Metastatic Castration-resistant Prostate Cancer' on Aug. 14.

Brief Summary: The purpose of this study is to determine the safety and efficacy of 225Ac -labeled PSMA ligand(PSMA-XT) in the treatment of mCRPC

Study Start Date: Oct. 14, 2024

Study Type: INTERVENTIONAL

Condition: Metastatic Castration-Resistant Prostate Cancer Patients

Intervention: DRUG: 225Ac-PSMA-XT

Patients will receive 225Ac-PSMA-XT administration at an interval of 6 weeks between each dose.

Recruitment Status: RECRUITING

Sponsor: ...